Abstracts tagged "Patient reported outcomes"

Abstract Number: 0479 • ACR Convergence 2023
Exploring Reproductive Experiences with Women Enrolled in the Vasculitis Pregnancy Registry
Catherine Sims¹, Christine Yeung², Heather Tam³, Joyce Kullman⁴, Amanda Eudy⁵, Renee Borchin⁶, Cristina Burroughs⁶, Megan Clowse⁷ and Peter Merkel², ¹Duke University School of Medicine, Durham, NC, ²University of Pennsylvania, Philadelphia, PA, ³Vasculitis Patient Powered Research Network, Stanford, CA, ⁴Vasculitis Foundation, Kansas City, MO, ⁵Duke University, Raleigh, NC, ⁶University of South Florida, Tampa, FL, ⁷Duke University, Chapel Hill, NC
Background/Purpose: There are limited data on the reproductive health and experiences of women with vasculitis. This study engaged women with vasculitis to understand their perspectives…
Abstract Number: 0810 • ACR Convergence 2023
Telehealth Utilization and Satisfaction Among Patients with Rheumatic Diseases: Trends Since the Onset of the COVID-19 Pandemic
Kristin Wipfler¹ and Kaleb Michaud², ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The COVID-19 pandemic prompted a rapid transition to increased telehealth utilization, with many rheumatology providers replacing in-person clinical visits with telehealth visits or expanding…
Abstract Number: 1214 • ACR Convergence 2023
Using Patient Self-Reported Measures to Predict All-Cause Hospitalization in a Population-Based Lupus Cohort
S. Sam Lim¹, Sandra Wu², Ryan Ross³, Gaobin Bao¹, Megan Richards³, Liisa Palmer³ and Gary Bryant⁴, ¹Emory University, Atlanta, GA, ²AstraZeneca, Hockessin, DE, ³Merative, Cambridge, MA, ⁴AstraZeneca, New Castle, DE
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that affects the skin, joints, kidneys, lungs, central nervous system, and hematopoietic system. As a…
Abstract Number: 1390 • ACR Convergence 2023
Prediction of Low Disease Activity in Patients with Ankylosing Spondylitis Treated with Secukinumab in Real World – Data from a German Observational Study
Asmir Vodencarevic¹, Jan Brandt-Juergens², Daniel Peterlik¹, Benjamin Gmeiner¹ and Uta Kiltz³, ¹Novartis Pharma GmbH, Nürnberg, Germany, ²rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Secukinumab (SEC) proved to be an effective treatment for patients suffering from ankylosing spondylitis (AS) in randomized clinical trials [1]. There is only limited…
Abstract Number: 1910 • ACR Convergence 2023
Development of the American College of Rheumatology Toolkit for Implementation of Rheumatoid Arthritis Outcome Measures in Clinical Practice
Catherine Nasrallah¹, Lindsay Jacobsohn¹, Gabriela Schmajuk², Emma Kersey¹, Cammie Young³, Cammie Young³, Janell Martin⁴, Lori Barber⁵, Jennifer Barton⁶, Puneet Bajaj⁷, Christie M. Bartels⁸, Sancia Ferguson⁹, Elizabeth Wahl¹⁰, Kimberly DeQuattro¹¹, Patti Katz¹², Maria I. ("Maio") Danila¹³, Meera Subash¹⁴, Christina Downey¹⁵, JoAnn Zell¹⁶, Kimberly Reiter¹⁷, Elena Weinstein¹⁸ and Jinoos Yazdany¹, ¹University of California San Francisco, San Francisco, CA, ²UCSF / SFVA, San Francisco, CA, ³University of California San Francisco, Oakland, CA, ⁴American College of Rheumatology, Atlanta, GA, ⁵ACR, Atlanta, GA, ⁶VA Portland Health Care System/OHSU, Portland, OR, ⁷UT Southwestern Medical Center, Dallas, TX, ⁸University of Wisconsin, School of Medicine and Public Health, Madison, WI, ⁹University of Wisconsin, Madison, WI, ¹⁰VA Puget Sound Healthcare System, Seattle, WA, ¹¹University of Pennsylvania, Media, PA, ¹²University of California San Francisco, San Rafael, CA, ¹³University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ¹⁴University of Texas Health Science Center at Houston, Houston, TX, ¹⁵Loma Linda University Medical Center, Loma Linda, CA, ¹⁶University of Colorado Anschutz Medical Campus, Denver, CO, ¹⁷Albuquerque VA Medical Center, Albuquerque, NM, ¹⁸University of Colorado, Englewood, CO
Background/Purpose: Despite significant interest in the scale and spread of rheumatoid arthritis (RA) outcome measures to facilitate a patient-centered, treat-to-target approach, use of these measures…
Abstract Number: 2126 • ACR Convergence 2023
Performance of the Rheumatoid Arthritis Impact of Disease (RAID) Score in Relation to Flares in Disease Activity
Karen Holten, Nina Paulshus Sundlisæter, Joseph Sexton, Lena Bugge Nordberg, Till Uhlig, Tore Kvien, Espen Haavardsholm, Siri Lillegraven and Anna-Birgitte Aga, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: The Rheumatoid Arthritis Impact of Disease (RAID) is a patient-reported outcome measure (PROM) originating from a EULAR initiative. It might support patient-centred care and…
Abstract Number: 2270 • ACR Convergence 2023
Factors Associated with Discordance Between Patient and Physician Perception of Disease Activity Among Patients with Systemic Lupus Erythematosus: An International Collaborative Study
Shounak Ghosh¹, Rajagopal Sankara Narayanan², Katie Bechman³, Ioannis Parodis⁴, Esha Kadam⁵, Wanruchada Katchamart⁶, Phonpen Akarawatcharangura Goo⁷, Abraham Edgar Gracia-Ramos⁸, Parikshit Sen⁹, Elena Nikiphorou³, Sreoshy Saha¹⁰, Ai Lyn Tan¹¹, Tsvetelina Velikova¹², Marcin Milchert¹³, Johannes Knitza¹⁴, Carlo Caballero¹⁵, Dey Dzifa¹⁶, Hector Chinoy¹⁷, COVAD Study Group¹⁸, Rohit Aggarwal¹⁹, Vikas Agarwal²⁰, Latika Gupta²¹ and Chris Wincup²², ¹CMRI Hospital, Kolkata, India, ²Narayana Medical College, Nellore, India, ³King's College London, London, United Kingdom, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Seth Gordhandhas Sunderdas Medical College and King Edwards Memorial Hospital, Mumbai, India, ⁶Mahidol University, Bangkok, Thailand, ⁷Department of Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand, ⁸Department of Internal Medicine, General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P. 02990, Mexico City, Mexico, ⁹Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, ¹⁰Mymensingh Medical College, Faridpur, Bangladesh, ¹¹University of Leeds, Leeds, United Kingdom, ¹²Department of Clinical Immunology, Medical Faculty, University Hospital "Lozenetz", Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹³Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, ¹⁴Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ¹⁵Universidad del Norte, Barranquilla, Colombia, ¹⁶Department of Medicine and Therapeutics, University of Ghana School of Medicine and Dentistry, College of Health Sciences, Korle-Bu, Accra, Ghana, ¹⁷The University of Manchester, Sale, United Kingdom, ¹⁸-, -, ¹⁹University of Pittsburgh, Pittsburgh, PA, ²⁰Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²¹Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom, ²²King's College Hospital, London, United Kingdom
Background/Purpose: The management of SLE relies on regular assessment of disease activity. However, patient perception of disease activity can be highly variable and may be…
Abstract Number: 0338 • ACR Convergence 2023
Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis or Ankylosing Spondylitis: Data from COVAD Patient-reported E-survey
Diego Benavent¹, Marco Fornaro², Florenzo Iannone³, Lorenzo Cavagna⁴, Masataka Kuwana⁵, Naveen R⁶, Vishwesh Agarwal⁷, Jessica Day⁸, Mrudula Joshi⁹, Sreoshy Saha¹⁰, Kshitij Jagtap¹¹, Wanruchada Katchamart¹², Phonpen Akarawatcharangura Goo¹³, Binit Vaidya¹⁴, Tsvetelina Velikova¹⁵, Parikshit Sen¹⁶, Samuel Shinjo¹⁷, Ai Lyn Tan¹⁸, Nelly Ziade¹⁹, Marcin Milchert²⁰, Abraham Edgar Gracia-Ramos²¹, Carlo Caballero²², Hector Chinoy²³, Vikas Agarwal⁶, Rohit Aggarwal²⁴, Latika Gupta²⁵ and Vincenzo Venerito²⁶, ¹Hospital la Paz, Madrid, Spain, ²University of Bari, Grottaglie, Italy, ³Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ⁴Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁵Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁶Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁷Mahatma Gandhi Missions Medical College, Lucknow, India, ⁸Walter and Eliza Hall Institute, Melbourne, Australia, ⁹Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ¹⁰Mymensingh Medical College, Faridpur, Bangladesh, ¹¹Seth Gordhandhas Sunderdas Medical College and King Edwards Memorial Hospital, Mumbai, India, ¹²Mahidol University, Bangkok, Thailand, ¹³Department of Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand, ¹⁴National Center for Rheumatic Diseases (NCRD), Ratopul, Kathmandu, Nepal., Kathmandu, India, ¹⁵Department of Clinical Immunology, Medical Faculty, University Hospital "Lozenetz", Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹⁶Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, ¹⁷Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, Brazil, ¹⁸University of Leeds, Leeds, United Kingdom, ¹⁹Saint-Joseph University, Beirut, Lebanon, ²⁰Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, ²¹Department of Internal Medicine, General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P. 02990, Mexico City, Mexico, ²²Universidad del Norte, Barranquilla, Colombia, ²³The University of Manchester, Sale, United Kingdom, ²⁴University of Pittsburgh, Pittsburgh, PA, ²⁵Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom, ²⁶Rheumatology Department, Università degli Studi di Bari, Bari, Italy
Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA), including either Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS), are some of the most commonly diagnosed autoimmune rheumatic…
Abstract Number: 0488 • ACR Convergence 2023
Factors Associated with Work Productivity Among Individuals with Psoriatic Arthritis (PsA) and Psoriasis (PsO): The Role of Patient Reported Outcomes and Disease Severity
Nancy Shadick¹, Kumiko Schnock², Vivi Feather³, Ruogu Li², Jing Cui¹, Shivani Patel², Sabrina Goutier¹, Muibat Yussuff², Lourdes Perez-Chada², Michael Weinblatt⁴ and Joseph Merola⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Mass General Brigham, Boston, MA, ⁴Harvard Medical School, Waban, MA, ⁵Harvard Medical School, Brigham and Women's Hospital, Newton, MA
Background/Purpose: Patients with Psoriatic Arthritis (PsA) and Psoriasis (PsO) have an increased rate of work loss due to their disease compared the general population; however,…
Abstract Number: 0823 • ACR Convergence 2023
Sleep Disturbance Predicts Pain Interference in Patients with Early Rheumatoid Arthritis in a Prospective Real-World Cohort
Burcu Aydemir¹, Orit Schieir², Marie-France Valois³, Lutfiyya Muhammad¹, Jing Song¹, dorothy Dunlop¹, Susan Bartlett⁴, Louis Bessette⁵, Gilles Boire⁶, Glen Hazelwood⁷, Carol Hitchon⁸, Edward Keystone⁹, Janet Pope¹⁰, Carter Thorne¹¹, Diane Tin¹², Vivian Bykerk¹³, Yvonne Lee¹⁴ and Canadian Early Arthritis Cohort (CATCH) Investigators¹⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²McGill University, Montréal, QC, Canada, ³McGill University, Pointe-Claire, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ⁶Université de Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Manitoba, Manitoba, MB, Canada, ⁹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Newmarket Rheumatology Consultants, Newmarket, ON, Canada, ¹³Department of Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁴Northwestern University, Chicago, IL, ¹⁵CATCH, Winnipeg, MB, Canada
Background/Purpose: Despite taking strong immunosuppressive medications to control inflammation, many patients with rheumatoid arthritis (RA) continue to experience moderate to severe pain that does not…
Abstract Number: 1216 • ACR Convergence 2023
“I Call It Zombie Hands and Feet, That’s Actually How I Found out I Had This Disease”: Disease Symptoms and Treatment Side Effects in a Diverse Sample of Patients with Early Limited Cutaneous and Diffuse Cutaneous Systemic Sclerosis
Chelsea Perschon¹, Emilie Jaeger¹, George Greene¹, Alain Lescoat², Yen Chen³, Susan Murphy³, Sara Shaunfield¹, David Cella¹ and Dinesh Khanna³, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²University Rennes, Rennes, France, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune rheumatic disease with heterogeneous manifestations, including common symptoms such as pain, fatigue, dyspnea, and Raynaud's phenomenon. It…
Abstract Number: 1412 • ACR Convergence 2023
Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients with Active Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J. Mease¹, Alexis R Ogdie², John Tesser³, Natalie shiff⁴, Iris Lin⁵, Soumya Chakravarty⁶, Mike Kelleman⁷, Rhiannon Dodge⁷, Robert McLean⁷, Aaron Broadwell⁸, Arthur Kavanaugh⁹ and Joseph F. Merola¹⁰, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁴Immunology, Janssen Scientific Affairs, LLC / Adjunct, Community Health and Epidemiology, University of Saskatchewan, Horsham, PA, ⁵Janssen, Horsham, PA, ⁶Immunology, Janssen Scientific Affairs, LLC / Division of Rheumatology, Drexel University College of Medicine, Villanova, PA, ⁷CorEvitas, LLC, Waltham, MA, ⁸Department of Rheumatology, Rheumatology and Osteoporosis Specialists, Shreveport, LA, ⁹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ¹⁰Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Guselkumab (GUS) has demonstrated significant efficacy across disease domains in controlled clinical trials of patients (pts) with active PsA.1,2 Recent CorEvitas PsA/SpA Registry analyses…
Abstract Number: 1911 • ACR Convergence 2023
Using the Technology Acceptance Model to Assess Physician Perceptions and Experiences Using the Rheumatoid Arthritis-Patient-Reported Outcomes Dashboard: Mixed-Methods Study
Catherine Nasrallah¹, Cherish Wilson², Alicia Hamblin¹, Lindsay Jacobsohn¹, Cammie Young³, Cammie Young³, Mary Nakamura⁴, Andrew Gross¹, Judith Ashouri¹, Mehrdad Matloubian¹, Jinoos Yazdany¹ and Gabriela Schmajuk², ¹University of California San Francisco, San Francisco, CA, ²UCSF / SFVA, San Francisco, CA, ³University of California San Francisco, Oakland, CA, ⁴UCSF/SFVAHCS, San Francisco, CA
Background/Purpose: Improving shared decision-making using a treat-to-target approach, including the use of patient reported outcomes (PROs), is important to providing high quality care for rheumatoid…
Abstract Number: 2156 • ACR Convergence 2023
Efficacy of Olokizumab in Comorbid Depressive Disorder in Patients with Rheumatoid Arthritis: Preliminary Results of a Study
Vibeke Strand¹, Tatiana Lisitsyna², Anton Abramkin², Dmitry Veltishchev³, Olga Seravina³, Oksana Kovalevskaya³, Anastasia Borisova⁴, Sofia Kuzkina⁵, Vasily Ignatiev⁵ and EVGENY NASONOV⁶, ¹Stanford University, Portola Valley, CA, ²V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ³Moscow Research Institute of Psychiatry branch of Serbsky National Medical Research Center for Psychiatry and Narcology of the Ministry of Health, Moscow, Russia, ⁴Moscow Research Institute of Psychiatry branch of Serbsky National Medical Research Center for Psychiatry and Narcology of the Ministry of Health, Mosocw, Russia, ⁵R-Pharm, Moscow, Russia, ⁶Scientific Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: Interleukin-6 (IL) plays an important role in the pathogenesis of comorbid rheumatoid arthritis (RA) depression, and IL-6 inhibitors used to treat RA patients may…
Abstract Number: 2279 • ACR Convergence 2023
Sociodemographic Features, Health-Related Quality of Life (HRQoL), Previous General Self-Efficacy and Corticosteroids (CS) Are Associated with General Self-Efficacy in Systemic Lupus Erythematosus (SLE) Patients. Data from a Prevalent Latin American Lupus Cohort
Manuel Ugarte-Gil¹, Rocío Gamboa-Cárdenas², Cristina Reategui-Sokolova³, Victor Pimentel-Quiroz², Claudia Elera-Fitzcarrald⁴, Jorge M. Cucho-Venegas⁵, Cesar Pastor-Asurza⁶, Zoila Rodriguez-Bellido⁶, Risto Perich-Campos⁶ and Graciela S Alarcón⁷, ¹Universidad Cientifica del Sur, Lima, Peru, ²Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, ³Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad San Ignacio de Loyola, Lima, Peru, ⁴Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad Privada San Juan Bautista, Lima, Peru, ⁵Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, ⁶Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁷Heersink School of Medicine. The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Self-efficacy is the belief that one can carry out a behavior necessary to reach a desired goal. A better self-efficacy has been reported as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].